Profile data is unavailable for this security.
About the company
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.
- Revenue in USD (TTM)1.04m
- Net income in USD-32.07m
- Incorporated2005
- Employees37.00
- LocationVistagen Therapeutics Inc343 ALLERTON AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 577-3600
- Websitehttps://www.vistagen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hongchang International Co Ltd | 2.67m | -365.80k | 103.82m | 8.00 | -- | 2.62 | -- | 38.93 | -0.0006 | -0.0006 | 0.0055 | 0.0763 | 0.0993 | -- | 175.86 | -- | -1.36 | -7.98 | -1.42 | -10.94 | 3.03 | 11.47 | -13.72 | -64.88 | 5.86 | -- | 0.2263 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Verastem Inc | 0.00 | -105.52m | 104.34m | 73.00 | -- | 4.16 | -- | -- | -4.40 | -4.40 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -86.34 | -62.70 | -108.04 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.4703 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -65.10m | 104.94m | 63.00 | -- | 0.4935 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Vor Biopharma Inc | 0.00 | -120.23m | 106.14m | 168.00 | -- | 0.8622 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 108.59m | 20.00 | -- | 0.9352 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.26m | 109.34m | 18.00 | -- | 2.36 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 110.26m | 37.00 | -- | 0.8944 | -- | 105.79 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Cellectar Biosciences Inc | 0.00 | -50.98m | 111.49m | 20.00 | -- | 11.35 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Yubo International Biotech Ltd | 455.72k | -1.26m | 112.03m | 18.00 | -- | -- | -- | 245.84 | -0.0105 | -0.0105 | 0.0038 | -0.0172 | 0.2488 | 0.4126 | 5.27 | 25,317.78 | -70.32 | -- | -- | -- | 80.24 | -- | -282.61 | -- | 0.1487 | -4,023.75 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Immunic Inc | 0.00 | -97.92m | 112.60m | 77.00 | -- | 1.35 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| PDS Biotechnology Corp | 0.00 | -43.89m | 112.97m | 25.00 | -- | 3.04 | -- | -- | -1.37 | -1.37 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -63.85 | -51.63 | -74.22 | -59.00 | -- | -- | -- | -- | -- | -27.82 | 0.3933 | -- | -- | -- | -5.11 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.38m | 113.99m | 13.00 | -- | 8.13 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 115.63m | 8.00 | -- | 3.57 | -- | 18.87 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Beyondspring Inc | 1.75m | -21.03m | 116.31m | 35.00 | -- | -- | -- | 66.42 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 117.48m | 93.00 | -- | 2.84 | -- | 23.79 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Vistagen Therapeutics Inc's reporting currency: US Dollar USD
47.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 2.00m | 7.40% |
| Great Point Partners LLCas of 31 Mar 2024 | 1.86m | 6.88% |
| StemPoint Capital LPas of 31 Mar 2024 | 1.85m | 6.84% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.78m | 6.60% |
| Commodore Capital LPas of 31 Mar 2024 | 1.58m | 5.83% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.52m | 5.62% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 808.55k | 2.99% |
| Citadel Advisors LLCas of 31 Mar 2024 | 743.50k | 2.75% |
| Armistice Capital LLCas of 31 Mar 2024 | 364.00k | 1.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 348.44k | 1.29% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
